Cardiac-Specific Inducible and Conditional Gene Targeting in Mice

Thomas Doetschman, Mohamad Azhar

Abstract: Mouse genetic engineering has revolutionized our understanding of the molecular and genetic basis of heart development and disease. This technology involves conditional tissue-specific and temporal transgenic and gene targeting approaches, as well as introduction of polymorphisms into the mouse genome. These approaches are increasingly used to elucidate the genetic pathways underlying tissue homeostasis, physiology, and pathophysiology of adult heart. They have also led to the development of clinically relevant models of human cardiac diseases. Here, we review the technologies and their limitations in general and the cardiovascular research community in particular. (Circ Res. 2012;110:1498-1512.)

Key Words: heart ■ inducible gene targeting ■ conditional knockout mice ■ transgenic mice ■ Cre recombinase

Cardiovascular disease is the leading cause of morbidity and death in the economically developed world.1,2 The heart is the first organ to form, but once developed it must maintain homeostatic processes to maintain function throughout life, and it must also be able to undergo repair and remodeling following stress and injury.3,4 Aging affects multiple organs, and the higher predisposition of the elderly to diseases such as diabetes and autoimmunity can bring complications to the homeostatic and remodeling processes of the adult heart. Such complications include aortic disease, valve dysfunction, cardiomyopathy, and heart failure.5 The genetically engineered mouse has emerged as a powerful tool not only for understanding cardiovascularogenesis, but also for understanding the pathogenesis of cardiac disease through animal modeling.5-7

The heart is composed of several cell types that distinguish it from other organs (Figure 1).4 Each has specific functions based on unique gene expression patterns that direct responses to its cellular, physiological, and stress environments.3 Approaches are therefore required to identify these functions at the animal level because this complexity cannot be fully recapitulated ex vivo, though hypotheses concerning signal pathway interactions can be quickly generated ex vivo followed by verification in the animal. Because genetic alterations can underlie congenital heart disease,8 and because susceptibility to heart disease can also result from gene polymorphisms, mice are a good choice for modeling the genetic basis of mammalian cardiovascular development and disease. Mice are mammals with a 4-chambered heart, their genes can be engineered in a highly specific manner and then expressed in both inducible and noninducible manners,9 the generation of genetically engineered mice is both cost and time effective relative to other mammals,5 and inbred strains of mice are available, which allow mutations to be introduced into defined genetic backgrounds.10

Hereditary forms of cardiovascular disease can be modeled through germline mutations, and nonhereditary forms of cardiovascular pathophysiology can be introduced in tissue-specific and inducible manners. Genes can be overexpressed or ablated in spatio-temporal fashion. Multiple gene defects can be combined or added in sequence through a combination of breeding and inducible systems. Polymorphisms can also be introduced in the germline or in tissue-specific and inducible manners. Similarly, the effects of microenviron-
ment and stress can be functionally tested through gene alterations in specific cardiac cell types and through alteration of the animal’s environment and application of stress conditions. Mouse strains with complex genetic combinations and highly controlled spatial and temporal regulation of genes now predominate the modeling of cardiac disease. In the fields of vascular biology (eg, aneurysm and hypertension), immunology and inflammation, and metabolic syndrome genetically engineered mice are also the predominant experimental tools. Because vascular and metabolic defects and inflammation can directly affect cardiac remodeling and function, the use of mouse modeling has been useful for improving our understanding of the pathophysiology of the heart.

In this review, a brief historical account of the field of mouse gene targeting will be followed by a general discussion of the benefits and limitations of the conditional and inducible approaches being introduced into mouse models to study gene function. Brief discussions of the use of these approaches in studying cardiac development and in modeling both congenital and adult congenital heart disease will then be followed by a specific example to signify the bench-to-bedside potential of this powerful technology. Because conventional transgenic and knockout (KO) techniques are now routine, we will not cover these approaches in detail. They have been recently reviewed elsewhere, as has cardiac-specific transgenesis.

Background of Mouse Gene Targeting and Transgenic Technology

Pluripotent cells that supported transplantable teratomas were reported in spontaneous teratomas from specific mouse strains. Teratocarcinoma cell lines were derived from those teratomas, and their pluripotency was demonstrated by blastocyst injection, but with little germline efficiency. ES cells, on the other hand, were isolated directly from the inner cell mass of mouse embryos, were subsequently shown to colonize the germline at practical frequencies, and were shown to be capable of transmitting transgenes through the germline in a generationally stable fashion. Gene targeting was achieved in ES cells through homologous recombination, and those ES cells could be used to stably transmit the targeted gene into a new strain of mouse. Finally, it was demonstrated that genes not expressed in ES cells could be targeted at the same frequency as expressed genes. Reviews on developments in gene targeting are available. These studies have provided the technical foundation for the development of mouse models that have

Non-standard Abbreviations and Acronyms

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>α-MHC</td>
<td>α-myosin heavy chain</td>
</tr>
<tr>
<td>AV</td>
<td>atrioventricular</td>
</tr>
<tr>
<td>CCS</td>
<td>cardiac conduction system</td>
</tr>
<tr>
<td>CMV</td>
<td>minimal cytomegalovirus promoter</td>
</tr>
<tr>
<td>CreER</td>
<td>Cre with the mutant ligand-binding domain of human estrogen receptor</td>
</tr>
<tr>
<td>Dox</td>
<td>doxycycline</td>
</tr>
<tr>
<td>EMT</td>
<td>epithelial mesenchymal transition</td>
</tr>
<tr>
<td>KO</td>
<td>knockout</td>
</tr>
<tr>
<td>miRNA</td>
<td>MicroRNA</td>
</tr>
<tr>
<td>NCC</td>
<td>neural crest cells</td>
</tr>
<tr>
<td>rtTA</td>
<td>reverse tetracycline controlled transactivator</td>
</tr>
<tr>
<td>tTA or rtTA</td>
<td>tTA</td>
</tr>
<tr>
<td>SNPs</td>
<td>single nucleotide polymorphisms</td>
</tr>
<tr>
<td>TALENs</td>
<td>transcription activator-like effector nucleases</td>
</tr>
<tr>
<td>Tam</td>
<td>tamoxifen</td>
</tr>
<tr>
<td>Tet</td>
<td>tetracycline</td>
</tr>
<tr>
<td>tetO</td>
<td>Tet operator</td>
</tr>
<tr>
<td>TetR</td>
<td>Tet repressor</td>
</tr>
<tr>
<td>Tnnt2</td>
<td>rat troponin T</td>
</tr>
<tr>
<td>tTA</td>
<td>tetracycline-controlled transactivator</td>
</tr>
<tr>
<td>ZFNs</td>
<td>zinc finger nucleases</td>
</tr>
</tbody>
</table>
led to a wave of second-generation genetically engineered mice with more complex genetic combinations and more highly controlled gene regulation. Genetic engineered mouse models are now being used in a preclinical setting to identify and validate novel diagnostic and therapeutic approaches for cardiovascular diseases.

Conditional and Inducible Gene Targeting

Conventional gene targeting, in which gene function is ablated in all cells of the body, is estimated (T.D.) to have produced most of the first 1000 gene KO mice, but it has limitations. In about 30% of the cases, KO mice exhibit embryonic or early postnatal lethality, which underscores the absolute gene requirement for embryogenesis and therefore obscures the analysis of the potential gene function at postnatal stages of life. Development of approaches for conditional (spatial control) and inducible (temporal control) mutation have been applied to overcome these limitations. The first successful in vivo description of cre transgenic mice was reported in 1992, followed by another study demonstrating that Cre recombination also worked in mouse ES cells. These initial reports revolutionized the conditional KO mouse field. In mice harboring conditional alleles, the target gene is modified in the germline so that it has the potential for future mutation but maintains wildtype gene function. This is done by flanking a critical gene region with loxP sites, which themselves are not in critical regions. The loxP sequences are recognition sites for Cre recombination. Through genetic combination with a tissue-specific cre transgene, those critical sequences between the loxP sites are recombined out, resulting in loss of gene function in that tissue. In addition to the Cre-loxP recombination system, FLP-FRT and Dre-rox systems are also available.

Temporal control over ablation of gene function can be achieved by using tamoxifen (Tam)-inducible and tetracycline (Tet), or its analog doxycycline (Dox)-inducible recombinases. The combination of both conditional and inducible gene targeting approaches has led to tissue-specific genetic alterations under temporal control. Temporal control over the conditional gene targeting event has enabled investigation of gene function during embryonic development and over time in adult mice as a model of aging. In addition, adenoaviral cre expression vectors can be delivered by intravenous or stereotaxic injection into mice, which can be effective tools for localized temporal regulation of cre expression in the target organ.

There are also problems with the Cre-locP system that must be kept in mind. Several studies have indicated significant Cre toxicity in mammalian cells and transgenic mice. This is consistent with the presence of cryptic loxP sites (1.2 primary cryptic loxP sites per Mb DNA) in the mouse genome, which could cause illegitimate DNA recombination. The Cre toxicity can be minimized by using floxed cre expression cassette in Cre mice, which terminates its own expression via self-deletion of the floxed cre. Another strategy to reduce Cre toxicity is to use regulated cre expression by inducible Cre mice (see below). Another technical concern regarding the use of Cre mice is that these mice either can exhibit phenotypic abnormalities and altered expression of genes at and around the site of random transgene insertion caused by the inherent problems associated with the transgenic mouse technology (ie, cre transgenic mice) or Cre mice may have subtle undesirable phenotypes because of their heterozygous KO status (cre knockin mice). Some of these concerns can also be minimized by using appropriate controls such as mice carrying the cre transgene but not its loxP-flanked target gene and Cre mice with a floxed heterozygous allele. There is no data to suggest any pitfalls in the use of FLP and Dre mice. Overall, numerous successful experiments using Cre mice indicates that despite many pitfalls the conditional gene targeting remains by and large the most useful technique in manipulating mouse genes in a tissue-specific fashion.

Conditional gene targeting typically requires crossing a gene with loxP sites flanking an exon (hereafter termed “floxed” mice) with mice carrying a cre transgene (hereafter termed Cre mice). These floxed alleles are introduced in mice using traditional gene targeting approaches, and the exon deletion is activated when the cre transgene is expressed. The Cre (P1 phage-derived) and Flip (FLP, yeast-derived) recombinases recognize 34 bp loxP and FRT (flippase recognition target) sites, respectively (Figure 2). FRT and loxP sequences have an asymmetry such that recombination between similarly oriented recognition sites in the same DNA strand results in a deletion of the intervening sequence. The recombination leaves a single loxP or FRT site. These recognition sites are not present in the mouse genome.

Because a positive selectable marker gene (eg, neomycin) that is often introduced to modify the locus could disrupt or alter the gene function or result in a hypomorphic locus, strategies have been developed for removal of the marker gene after the targeted allele has been identified or established in the germline. The commonly accepted strategy is to flank the selectable marker cassette with FRT sites and remove the intervening region with FLP recombinase. Another established procedure is to keep the marker gene beside one of the loxP sites and place a third loxP site on the other side of the marker after the critical exon that will be conditionally deleted. The marker gene can be efficiently removed by a partial Cre excision process, which leaves behind the floxed critical exon in the targeted locus. These strategies are shown in Figure 3 which provides an example of a European Conditional Mouse Mutagenesis Program/Knockout Mouse Project (see below) gene targeting strategy that contains features for expression marking, removal of selectable marker gene, and conditional/inducible gene inactivation capabilities.

Resources for Targeted ES Cells and Mice

Before embarking on a costly and time-consuming gene-targeting project it is best to determine whether the targeted gene is already present either in an ES cell line or a mutant mouse strain. The International Knockout Mouse Consortium (http://www.knockoutmouse.org) is generating ES cells and mice with KO and conditional/inducible-capable alleles for all protein coding genes. The International Knockout Mouse Consortium reports targeted ES cell lines for over 15,000...
genes (including 9000 conditional targeted alleles\textsuperscript{49}), and mice for about 10\% of these.\textsuperscript{50} The consortium consists of the Knockout Mouse Project, European Conditional Mouse Mutagenesis program, North American Conditional Mouse Mutagenesis Project, and Texas A&M Institute for Genomic Medicine. Targeted ES cells can be purchased by academic researchers at nonprofit organizations at affordable prices. The requirements for generating these targeted alleles were that they not only KO the gene, but that they have the potential for conditional/inducible inactivation, provide a marker gene for expression analysis, and have the capacity to remove promoter interference by the selection gene. Mice generated by the Knockout Mouse Project are reposited by the National Center for Research Resources (http://www.ncrr.nih.gov/comparative medicine/resource directory/rodents.asp). In addition, the Jackson Laboratories has a large mutant mouse resource (http://mousemutant.jax.org/), and the National Cancer Institute’s Frederick Cancer Research facility has a Mouse Models of Human Cancer repository (http://mouse.ncifcrf.gov/). These repositories are also a primary source for finding Cre and Flp mouse lines for Cre/LoxP and Flp/Frt gene targeting.

**Tam-Inducible Conditional Gene Targeting**

Cre activity can be tightly controlled in space and time. Inducible and global or cell-type-specific conditional gene deletion has been most frequently carried out by fusion proteins of Cre with the mutant ligand-binding domain of translocation systems. Cre and FLP recombinases recognize loxP (A) and FRT (B) sequences, respectively. These 34-bp sequences contain 13-bp inverted repeats flanking 8 bp unique sequence motifs that have directionality. When 2 loxP or 2 FRT sites line up a recombination occurs at the 8 bp motif. Depending on whether the 8-bp motifs are in the same or opposite orientation a deletion or insertion (C), inversion (D) or translocation (E) can occur.

---

**Figure 2. Cre and FLP recombinase systems.** Cre and FLP recombinases recognize loxP (A) and FRT (B) sequences, respectively. These 34-bp sequences contain 13-bp inverted repeats flanking 8 bp unique sequence motifs that have directionality. When 2 loxP or 2 FRT sites line up a recombination occurs at the 8 bp motif. Depending on whether the 8-bp motifs are in the same or opposite orientation a deletion or insertion (C), inversion (D) or translocation (E) can occur.

---

**Figure 3. Conditional gene targeting.** A European Conditional Mouse Mutagenesis Program/Knockout Mouse Project gene targeting strategy that contains features for expression marking, removal of selectable marker gene, and conditional/inducible gene inactivation. Homologous recombination results in “knockout (KO) first” alleles where gene function is ablated by a polyadenylation signal-mediated transcriptional stop at the end of the lacZ expression marker gene that is driven off the target gene promoter. Removal of the targeting cassette by a FLP recombinase germline deleter mouse leaves loxP sites flanking a “critical” exon resulting in mice harboring conditional/inducible-ready alleles. Alternatively, the original allele can be subjected to Cre recombinase to delete the critical exon which results in a lacZ-tagged, germline-null allele. SA indicates splice acceptor site; pA, poly A.
human estrogen receptor (CreER). Both CreER and its more refined version, the CreERT2, do not bind to endogenous estradiol, but they bind to synthetic estrogen receptor ligand 4-hydroxytamoxifen or Tam with high affinity (Figure 4). Generally, in the absence of hormone, estrogen receptors are largely located in the cytoplasm. Estrogen binding to the receptor translocates the receptor from the cytoplasm to the nucleus where it binds to DNA and regulates transcription of target genes. However, the Cre recombinases are inactive and remain in the cytoplasm but can be activated and translocated to the nucleus by Tam, thereby allowing for external temporal control of Cre activity. A CreERT2 mouse can be a transgenic or a knockin of the CreERT2 coding region into an endogenous gene.

ROSA26-CreERT2 mice were made by targeting CreERT2 into the ROSA26 locus. The ROSA26 locus located on mouse chromosome 6 is a constitutively expressed gene in all cell types. ROSA26 mutant mice are normal and viable. The high rate of homologous recombination at the ROSA26 locus has made it a preferred site for knocking in a single-copy transgene to achieve a stable and ubiquitous or conditional transgenic overexpression during development or in the adult. Thus, ROSA26-CreERT2 mice have ubiquitous Tam-induced Cre recombinase activity in adult mice. In addition, cell-type-specific CreERT2 mice such as cardiac-specific αMHC-CreERT2 (also called αMHC-MerCreMer) mice have been effectively used in cell-type-specific Tam-inducible gene targeting. In addition, Tam-inducible Cre recombinase has been effectively used to modify gene function in mouse embryos in utero and oral gavage can be administered via food (custom-made chow containing 0.4–1 g/kg Tam, Harlan), water intake (0.5–1 mg/mL), 5 consecutive days of either intraperitoneal injection (100 mL of 10 μg/mL Tam) or oral gavage (200 mg/kg).

A disadvantage of the Tam approach to induce constitutive or cell-type-specific gene manipulation in utero is the risk of embryo abortion and death (can occur after 4 days of treatment), so it is useful only during those 4 days. Because RNAs and proteins have different half-lives and can function at different concentration ranges, it is possible that residual RNA or proteins present before the induced inactivation could compensate for gene inactivation. Assessment of both RNA and protein can test for this potential problem. Intestinal problems from Tam administration have also been reported in homozygous ROSA26-CreERT2 mice. There are also some concerns that Tam can cause behavioral alterations. The effects of Tam on CreERT2 mice alone, CreERT2 mice with the floxed allele, and mice harboring the conditional allele alone should be compared to the experimental mice (CreERT2 mice with the floxed-out conditional allele). Despite these potential problems, numerous researchers have successfully used this approach to investigate cardiac-specific gene function in the physiology and pathophysiology of the heart.

Tetracycline-Inducible Conditional Gene Targeting

Tet-mediated recombination is another widely used method for inducible gene targeting. This approach is reversible, it can control gene expression in either cell- or lineage-specific manners, and it can be temporally regulated. This system is derived from E. coli and has been adapted for use in eukaryotes. The 2 major components of this system are the Tet repressor (TetR) and the tet operator (tetO), which were originally derived from the Tn10 Tet resistance operon. Both Tet and its analog doxycycline (Dox) interact with TetR and are well tolerated and widely used in mammalian systems. Both Tet-OFF and Tet-ON approaches have been used to regulate gene expression in mice. In the Tet-controlled transactivator (TetC) or Tet-OFF system, Tet or Dox prevents binding of Tet to the Tet-responsive promoter (contains minimal cytomegalovirus [CMV] promoter and 7 tandem tetO [tetO7] sequences), and thus abolishes gene transcription. In contrast, the reverse Tet controlled transactivator (rtTA) or Tet-ON system requires Tet or Dox for binding to and inducing a Tet-responsive promoter (Figure 5).

The first demonstration of the Tet system in transgenic mice used the Tet approach in which E. coli’s Tn10 transposon fused to the VP16 transactivation domain from herpes simplex virus was used as a TetR for the Tet effector.
molecule. Gene induction became detectable in a few hours and reached its maximum level within a day. Several studies have indicated that the rtTA system is better suited for temporal control of rapid induction of gene expression.

Recently, many investigators have combined the Tet-inducible system with the Tam-inducible Cre-loxP approach (Figure 5). This allows more flexibility producing more clinically relevant mouse models of human diseases. Several laboratories have integrated the Tet-inducible and Cre-loxP approaches and developed mice based on rtTA-dependent Dox-mediated gene induction following a Cre-mediated deletion to obtain a temporal and spatial or cell-, tissue-, and organ-specific gene targeting. Thus, gene targeting can be manipulated in specific cell types and lineages with a flexibility that is difficult to achieve with other methods. To make this system more sophisticated, a Tet-inducible CreERT2 has been targeted to the ROSA26 locus. By introducing Tet induction, this Tam-inducible Cre driver line permits highly selective dual Tet and Tam regulation of the transgene of interest which could open new avenues for spatiotemporally controlled gene targeting in mice.

There are pitfalls inherent in Tet-inducible technology that is worth mentioning. The Tet system can be leaky. This can occur either through weak binding of rtTA to tetO even in the absence of Tet or Dox effectors, or through unwanted basal activity of the Tet-responsive promoter even in the absence of rtTA. This leakiness can result in unexpected phenotypes when Tet is absent. Although this leakiness can be tolerated in many experimental systems in which a phenotypic outcome are desired, it can be limiting when gene function is being investigated. Use of several Cre transgenic lines could obviate some of these difficulties. Refinements have also been made to rtTA (ie, rtTA2-S2-M2) to increase the sensitivity of the system and to reduce background expression. Additional control over background expression can also be achieved by using an inducible transcriptional repressor that can bind to the Tet-responsive promoter and thereby block background expression. For example, the TetR protein can be used to minimize leakiness in the system. In theory it is possible that the application of a tTA repressor with rtTA in the absence of Tet could prevent leaky expression through its binding to the TRE. This means that in the presence of Tet, Tet would bind to the tTA repressor and dissociate from the TRE, while at the same time the Tet-tTA complex would bind to the TRE and induce transcription. Although initial efforts to test these possibilities have produced mixed results, refinements could be promising.

Another potential problem with the Tet system is that of tissue toxicity caused by overexpression of TetR proteins. This can also be avoided by producing multiple transgenic lines expressing varying levels of Tet repressor. Taken together, it is very important that proper control animals are used in Tet-inducible gene targeting experiments to avoid misleading results due to these pitfalls. Overall, the ability to regulate gene activity in spatiotemporal and reversible fashions has made the Tet-inducible approach a favorite technology of numerous mouse geneticists.

**Figure 5. Tetracycline-inducible conditional gene targeting.** The Tet system can be used to conditionally activate gene expression in the mouse. A, In Tet-ON system Dox-binding to reverse tetracycline controlled transactivator (rtTA) leads to transcriptional activation of transgene. B, In the Tet-OFF system the tTA binds to tetO and induces transcription in the absence of Dox. In the presence of Dox the transgene expression is prevented. C, The boxed region indicates another application of the Tet-inducible transgenic mouse technology. In this example, tissue-specific (TS) Cre recombinase can be used to globally activate rtTA (Tet-ON) in R26rtTA knock-in mice. When these 2 mice are crossed to a tetO transgenic mice, and when the triple transgenic mice are subjected to Dox-induction, the transgene of interest can be expressed in a Dox-inducible fashion. tTA indicates tetracycline-dependent transactivator; Dox, doxycycline (ligand); tetO, Tet-responsive element.

**Targeting Single Nucleotide Polymorphisms Into the Mouse Genome**

There are numerous examples of single nucleotide polymorphisms (SNPs) in both exons and introns, and also important functionally relevant regulatory noncoding sequences and enhancer sequences within intronic regions. Several epidemiological studies have suggested that SNPs may be involved in the susceptibility and pathogenesis of cardiac disease in humans, and it is known that functionally relevant SNPs can be in noncoding regulatory and intronic regions. For example, about one-third of mammalian coding transcripts are silenced by microRNAs (miRNAs), powerful regulators of gene expression that are involved in cardiac development and pathogenesis of cardiac disease. Although conventional or conditional gene targeting has been used in introducing SNPs, which were created by site-directed mutagenesis in the targeting vector, in most instances a residual loxP site is left behind, sometimes accompanied by a selectable marker gene such as neomycin. The concern is that insertion of a selectable marker and/or loxP or FRT site(s) in noncoding intronic regions could cause lethality, or...
a hypomorphic or other unwanted phenotype. This makes it difficult to separate the effect of neomycin or loxP from the effect of the SNP. At the vector design stage incorporating bioinformatic approaches such as TraFac, which provides information on the conserved cis sequences within a gene, or ORF and miR analysis to detect other embedded genes, can usually identify regions in the gene that should be avoided when placing loxPs, FRTs, and selectable cassettes. However, these approaches are not completely accurate, and there are undoubtedly other functionally relevant sequence motifs not yet identified.

Consequently, it may be worthwhile not to leave behind residual sequences that in and of themselves could complicate phenotype analysis. We have previously reported on the use of a Tag and Exchange gene targeting approach to introduce point mutations in the basic fibroblast growth factor gene to ablate the function of protein isoforms resulting from alter-

Nuclease-Mediated Gene Targeting

Zinc finger nucleases (ZFNs) are custom-engineered DNA-binding modules fused to the catalytic domain of FokI endonuclease that have been adopted for targeted editing of the mouse and rat genome (Figure 6). \(^{8,9}\) ZFNs are eukaryotic transcription factors that bind 3 bp of DNA per finger; binding site specificity depends on key residues within the \(\approx 30\) aa ZFNs. The FokI cleavage domain can render a double-strand break at any user-specific sequence in the genome but must dimerize to be functional. Therefore, it is possible to cut within a unique genomic sequence of 18 to 24 nucleotides by designing a dimerizing pair of ZFNs, each containing a set of 3 to 4 strategically chosen ZFNs joined to a FokI catalytic domain (up to 6 fingers per monomer have been used). A donor DNA can be exogenously supplied to affect repair of the break by a homology-driven homologous recombination process, resulting in targeted gene replacement with a desired sequence. Alternatively, a double strand break stimulates the cellular process of nonhomologous end joining and results in the mis-repair of the DNA sequence. This error-prone process results in a KO genotype/phenotype. \(^{90}\)

ZFNs can be introduced directly into fertilized single cell embryos in plasmid or mRNA form. The embryos are implanted into the foster mother and the newborn founder animals are identified by standard screening methods. KO mice and rats can be generated in about 4 months at remarkably high efficiencies (monoallelic 10%–15%, biallelic 1%) compared to the conventional ES cell based gene targeting approach in mice that usually takes about 9 months to a year. The ZFN break-induced events are somewhere between 1,000- and 1,000,000-fold more efficient than the conventional ES cell targeting and there is no need to use selection to find the targeted products. A major difficulty in reproducibly applying the ZFN technology is the fact that it is difficult to design the zinc finger set with the highest probability of successfully cutting the user-specified location in the genome. There is also a potential risk of off-target cleavage by ZFNs. This is also due to a lack of known fingers for some nucleotide triplets and context effects on the specificities of individual fingers in an array.

Another class of engineered nucleases, transcription activator-like effector (nucleases (TALENs) appears to overcome some of the challenges facing the ZFN technology. \(^{91}\) Similar to ZFNs, TALENs are made by fusing the catalytic domain of
FokI to transcription activator-like effector repeat modules that are custom combined to target a unique stretch of genomic nucleotide sequence. Transcription activator-like effectors harbor ≈34 amino acid repeat domains that each binds 1 target base in the host genome with base specificity determined by 2 variable amino acids (Figure 6).92 TALENs have been successfully used in creating heritable changes in both zebrafish and rats.93,94 However, there are no genomically targeted mouse models generated using TALENs technology. Advantages of TALENs are that they are more designable than ZFNs because each module of TALENs binds 1 bp of DNA instead of 3 in ZFNs, and the TALEN specificity seems to be less influenced by neighboring DNA sequences. The TALENs also seem to be better than ZFNs at being restricted to their designed target. However, a limitation with TALENs is that the constructs for the TALENs are bigger than for ZFNs, largely because each module of 34 amino acids recognizes only 1 bp in the TALENs; whereas, each ZFN module of 30 amino acids recognizes 3. Although it is possible in principle to conditionally modify an allele for a tissue-specific disruption or overexpression using nuclease-mediated gene targeting techniques, a proof of principle experiment is still missing. Overall, nuclease-mediated gene targeting technology is at the cutting edge and needs to be developed further.

**Mouse Models for miRNA Expression**

miRNAs are 21 to 23 nucleotide long single-stranded RNAs. miRNAs are involved in numerous diverse cellular and developmental processes, and in the pathogenesis of several diseases, including cardiovascular disease.95 Sequence-specific base pairing of miRNA with target mRNAs reduces protein stability and translation. At least 30% of protein-coding genes appear to be conserved targets for miRNAs.95 The influence and importance of miRNAs as regulators of gene expression has led to their intensive study in the cardiovascular system.96 Only a limited number of individual miRNA KO mice have been described in the literature. Overall, several mouse models of miRNA expression have been successfully made by individual investigators using conditional mouse gene targeting approaches.97,98

The application of inducible technology in the field is growing rapidly.99 The analysis of miRNA KO alleles is complicated by the presence of several miRNA genes with related predicted specificities at multiple loci.100 Consequently, analysis of miRNA function will require the creation of tissue- or cell type-specific conditional and inducible as well as compound mutant mice of miRNA family members. The miRNA KO resource is a research toolbox of mutant alleles that can be used as reagents for studying miRNA function in a range of complementary approaches.101 The targeted alleles have been designed to be adaptable research tools that can be efficiently altered by recombinase-mediated cassette exchange to create reporter, conditional, and other allelic variants. Other examples of possible applications might include the variation of miRNA copy number and mutating individual miRNAs within clusters. This miRNA KO resource can be searched electronically and is available from ES cell repositories (http://www.knockoutmouse.org/martsearch).102 Finally, it is yet to be seen whether emerging technologies such as nuclease-mediated gene targeting can successfully manipulate miRNA in conditional or inducible fashion.

**Manipulating Alternatively Splicing of Genes Through Gene Targeting**

Many mammalian genes undergo alternative splicing.102 Alternative splicing results in the differential inclusion or exclusion of a specific exon in different cell types, retention of introns, exclusion of a portion of an exon, and mutually exclusive inclusion of exons.103 Importantly, any of these differential patterns have the potential to alter the open reading frame of the resultant mRNA or modify the cis-regulatory elements that control mRNA stability or translation. Thus, the proper regulation of alternative splicing is important for maintaining cellular protein repertoire, and changes in splicing can significantly alter cellular function. Gene targeting in mice has been used to create in vivo models to study the regulation and consequences of alternative splicing.104–106 The evidence accumulated so far argues for an important role of alternative splicing in mammalian development and tissue function, and highlights the importance of various protein isoforms in vivo.

Various approaches have been used to generate mice with modified alternatively spliced forms (Figure 7). Briefly, conditional mouse genetics approaches can be used to manipulate alternative splicing of a gene in a tissue-specific fashion.

**Figure 7. Mouse genetic engineering to manipulate alternative splicing in mice.** Three exons (1–3) in a gene are shown. Three examples are provided to splice out or delete Exon 2 (black box). A, Exon 2 is floxed and can be deleted in conditional/inducible fashion. B, One STOP codon can be introduced along with the marker gene into the gene using random retroviral insertion or gene trap method. C, Depletion of isoforms containing Exon 2 by causing the destruction of the splice site. See text for details.
fashion. Furthermore, a stop codon can be placed to eliminate expression of all alternatively spliced isoforms carrying an upstream exon, but allowing expression of downstream exons containing alternatively spliced variants. Another similar approach is to destroy the splice sites of the target exon. Furthermore, 1 exon can be replaced by another exon or an unrelated coding region to obtain the expression of an isoform in a tissue, where it is usually not expressed. This technique requires careful consideration of the targeting construct, as exonic regulatory sequences of the deleted exon might be important for tissue-specific splicing of the gene. Random retroviral insertion of marker genes and subsequent sequencing of the integration site has also generated many unrelated coding regions, loxPs, and other gene modification can be made along with the marker gene into the gene. A conventional approach is to destroy the splice sites of the target exon. Furthermore, 1 exon can be replaced by another exon or an unrelated coding region to obtain the expression of an isoform in a tissue, where it is usually not expressed. This technique requires careful consideration of the targeting construct, as exonic regulatory sequences of the deleted exon might be important for tissue-specific splicing of the gene. Random retroviral insertion of marker genes and subsequent sequencing of the integration site has also generated many commercially available targeted ES cells. In this method, stop codons, loxPs, and other gene modification can be made along with the marker gene into the gene. A conventional KO is used to eliminate the whole or parts of the gene to disrupt specific alternatively spliced isoforms. In the case of a partial removal of a gene, the expression of the resultant truncated form of alternatively spliced variant mRNA and protein should be taken into consideration. Lastly, the utility of ZFNs and TALENs in conditional or inducible gene targeting to manipulate alternative splicing in mice remains to be tested.

**Cardiac Cell Type-Specific Inducible Gene Targeting in Mice**

Several important genes that are involved in human cardiovascular disease are expressed in multiple cardiac cell types (Figure 1). In addition, the foundation of many adult congenital cardiovascular diseases can be traced to abnormal cardiovascular development.3,6,107 Thus, careful mutational analysis of genes in multiple cardiac cell lineages during development and into the adult heart is required to delineate the complex function of many genes in the heart. Tam- and Tet-inducible strategies have been applied to achieve this end6,7,108 and have been successful in demonstrating gene function in cardiac structure and function, cardiac physiology and pathophysiology, cardiomechanics, cardiac calcium handling, and cardiac stress response.11 In clinical terms, the development of cardiac-inducible/reversible gene targeting approaches provide translational potential.9 Because of the success and feasibility of cardiac-specific inducible gene targeting, the number of inducible cardiac cell-type-specific Cre mice is increasing (see the tetmouse database: www.creline.org). Here, we briefly describe the importance and practical aspects of some of the major cardiac lineage-specific CreERT2 and rtTA driver lines (Table).

**Myocardium**

The human α-myosin heavy chain (αMHC)33,68,109,110 and rat troponin T (Tnnt2)111 promoters are prominently used in Tam- and/or Tet-inducible gene targeting strategies for the heart. Because both αMHC and Tnnt2 are significantly expressed in the heart during embryonic development, inducible strategies must be used to drive Cre or rtTA in the postnatal heart.112,113 Tamoxifen-regulated αMHC-CreERT2 mice are by far the most extensively used.33 Inducible myocardial gene targeting in adult hearts has also been achieved by RU486 (antiprogestin)-inducible αMHC-CrePR1 mice.109

---

**Table. Validated Mouse Models for Cardiac-Specific Inducible and/or Conditional Gene Targeting**

<table>
<thead>
<tr>
<th>Cardiac Cell Type</th>
<th>Cre Mice</th>
<th>Cre Expression</th>
<th>Induction</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myocardium</td>
<td>αMHC-CreER12</td>
<td>Myocardium</td>
<td>Tamoxifen</td>
<td>33</td>
</tr>
<tr>
<td></td>
<td>αMHC-CrePR1</td>
<td></td>
<td>RU486</td>
<td>109</td>
</tr>
<tr>
<td></td>
<td>αMHC-tTA</td>
<td></td>
<td>Doxycycline</td>
<td>68</td>
</tr>
<tr>
<td></td>
<td>Tnnt2-rtTA/tetO</td>
<td></td>
<td>Doxycycline</td>
<td>111</td>
</tr>
<tr>
<td>Endothelium</td>
<td>Tie2-CreER12</td>
<td>Cardiac and vascular endothelium</td>
<td>Tamoxifen</td>
<td>123</td>
</tr>
<tr>
<td></td>
<td>VE-cadherin-CreER12</td>
<td>Cardiac and vascular endothelium</td>
<td>Tamoxifen</td>
<td>126</td>
</tr>
<tr>
<td></td>
<td>Tie2-rtTA/tTA</td>
<td>ND</td>
<td>Doxycycline</td>
<td>Tetmouse database</td>
</tr>
<tr>
<td>Cardiac and valvular fibroblasts</td>
<td>Tcf21-CreERT2</td>
<td>Epicardium, cardiac fibroblasts, valve interstitial cells</td>
<td>Tamoxifen</td>
<td>128</td>
</tr>
<tr>
<td></td>
<td>Col2-CreERT2</td>
<td>ND</td>
<td>Tamoxifen</td>
<td>130</td>
</tr>
<tr>
<td></td>
<td>αSMA-CreERT2</td>
<td>ND</td>
<td>Tamoxifen</td>
<td>134</td>
</tr>
<tr>
<td></td>
<td>SM22a-rtTA/tTA</td>
<td>ND</td>
<td>Doxycycline</td>
<td>Tetmouse database</td>
</tr>
<tr>
<td>Cardiac neural crest cells</td>
<td>Wnt1-CreERT2</td>
<td>ND</td>
<td>Tamoxifen</td>
<td>139</td>
</tr>
<tr>
<td>Epicardium</td>
<td>WT1-CreERT2</td>
<td>Epicardium, epicardium-driven cells</td>
<td>Tamoxifen</td>
<td>143</td>
</tr>
<tr>
<td></td>
<td>Tcf21-CreERT2</td>
<td>Epicardium, cardiac fibroblasts, valve interstitial cells</td>
<td>Tamoxifen</td>
<td>128</td>
</tr>
<tr>
<td>Cardiac conduction system</td>
<td>HCN4-CreERT2</td>
<td>SA node, AV node</td>
<td>Tamoxifen</td>
<td>148</td>
</tr>
<tr>
<td></td>
<td>Cx40-CreERT2</td>
<td>AV bundle, bundle branches, Purkinje fibers, atrial cardiomyocytes, coronary vessels</td>
<td>Tamoxifen</td>
<td>149</td>
</tr>
<tr>
<td></td>
<td>mink-CreERT2</td>
<td>AV node, AV bundle, bundle branches</td>
<td>Tamoxifen</td>
<td>150</td>
</tr>
</tbody>
</table>

αMHC indicates α-myosin heavy chain; CreER, Cre with the mutated progesterone receptor ligand binding domain; Tie2, tyrosine-protein kinase receptor TIE-2; Tcf21, transcription factor 21; Col2, collagen 2; αSMA, alpha smooth muscle actin; SM22a, SM22alpha; Wnt1, wingless-related MMTV integration site 1; WT1, Wilms tumor 1 homolog; HCN4, hyperpolarization-activated, cyclic nucleotide-gated K+-channel; VE-cadherin-CreERT2, epicardium, cardiac fibroblasts, valve interstitial cells; Tcf21, rat troponin T; rtTA, reverse tetracycline controlled transactivator; MHC-CreERT2, myocardium; Tnnt2, rat troponin T; rtTA, reverse tetracycline controlled transactivator; tetO, tetracycline operator; AV, atrioventricular.
There are some inherent pitfalls in using Tam or RU486 and an αMHC promoter to drive inducible cre expression in the postnatal heart. Tamoxifen is better tolerated than RU486 in both mouse embryos and adult mice, and therefore more investigators have preferred αMHC-CreERT2 over αMHC-CrePR1. Excess Cre levels in general can be toxic to cells, and in the heart there is evidence that high levels of cardiac cre driven by the αMHC promoter is cardiotoxic between 8 to 12 months of age.114 Another minor caveat with αMHC-CreERT2 mice is that Tam induction can temporarily cause cardiac dysfunction which, however, resolves after 1 to 2 weeks of treatment. In general, however, most of the problems associated with the use of CreERT2 mice can be avoided by using proper control mice.

Tet induction is another widely used approach to manipulate genes in myocardial-specific and inducible fashions in mouse embryos and adult mice. The rat αMhc promoter was initially used to drive rTA in transgenic mice.110 This strategy was inefficient for many investigators, probably due in part to promoter leakiness, thereby requiring several transgenic lines to get reliable data. Consequently, the mouse αMhc promoter was reengineered to drive low levels of rTA in transgenic mice.68 This resulted in more robust myocardial-specific transgene expression that can be controlled by Dox treatment. These investigators also found that modest to high levels of rTA can be cardiotoxic and can cause cardiac disease and lethality. Attempts to make αMHC-rtTA transgenic mice were not very successful.115

More recently, both rtTA and tetO binary components of the Tet-inducible system have been combined in transgenic mice (Tnt2-rtTA/tetO mice) in which the rat cardiac Tnn2 promoter drives the expression of rtTA, and tetO drives the cre. This Tnt2-rtTA effectively activates tetO cre expression in cardiomyocytes following Dox treatment. These investigators demonstrated that Tnt2-rtTA/tetO mice can be used to drive Dox-dependent myocardial-specific gene deletion in embryos and adults. More importantly, there seems to be no effect on cardiac structure and function in the absence or presence of Dox in Tnt2-rtTA/tetO mice alone. The obvious advantage of this system is that although it robustly drives cre expression in the entire myocardium, it also requires only 1 mouse line to cross with floxed mice to conditionally delete the gene. This system has already been adopted by other investigators116,117 and should attract more attention and scrutiny from the cardiac community.

One of the pitfalls in using Tet induction in Cre-loxP-based conditional KO experiments is that rtTA-driven cre expression acts as a trigger for Cre-mediated gene deletion. This leads to irreversible gene deletion in all of the descendant cells, even if Dox treatment is removed. This is in contrast to transgenic mice in which Dox allows for the induction of gene expression by addition or removal of Dox. Finally, there will always be concerns about differences in cardiac phenotypes that relate to characteristics of different myocardial promoters driving inducible cre. For example, the cardiac phenotypes of myocardial Smad4 conditional KO mice range from embryonic cardiac malformations (valves and myocardium) to cardiac hypertrophy in adults, depending on which myocardial promoters driving cre is used.118 Notably, the Smad4flox/flox mice used in all of these studies were of a common lineage,119 suggesting that the differences in the phenotypes related to the characteristics of the different myocardial promoters and not genetic background differences. Overall, however, it is possible to design carefully controlled experiments to harness the power of Tam- and Tet-inducible systems to regulate cre expression.

**Cardiac Endothelium and Fibroblasts**

There is evidence to suggest that defects in valve formation during embryonic development predispose patients to progressive postnatal valvular disease.31,107 The process of valve formation begins with an epithelial mesenchymal transition (EMT) (embryonic day [E] 9.5 to E10.5 in mice) that forms the endocardial cushions,120 which are the primordia of valves and septa, and which later become mature structures through remodeling (E10.5–E18.5) and valve elongation and maturation (E14.5–1 week after birth).121 During the maturation process the extracellular matrix of atrioventricular (AV) or outflow tract valves is organized into atrialis or ventricularis, spongiosa, and fibrosa layers.107 Cardiac cell lineage-specific analysis has found that the majority of valve mesenchyme is derived from the valve endocardium.122 Overall, there are 2 major cell types in adult cardiac valves that are represented by cardiac valve endocardium and valve interstitial cells or valvular fibroblasts (Figure 1).107

Tie2-Cre mice, which drive recombination in the entire endocardium and vascular endothelium, are the most extensively used Cre drivers in the cardiac valve community (reviewed 107). A Tam-inducible Tie2-CreERT2 has also been made and successfully applied in numerous systems.123 The obvious pitfall of this mouse line is that it is not specific to valve endocardium and that it also functions in the hematopoietic cell lineage.124 Recently, it has been reported that Tie2-Cre mice exhibit activity in the female germ line.125 Because this can result in the inheritance of a nontransgenic-specific KO allele in the second generation, careful breeding plans and appropriate controls are needed if Tie2-Cre promoters are used in inducible conditional gene targeting experiments. Some of the problems of Tie2-Cre mice are mitigated in VE-cadherin–CreERT2 mice,126 which also drive recombination in both the entire endocardium and vascular endothelium but which have minimal activity in the hematopoietic cell lineage. However, some investigators have reported less efficient cardiac endothelial-specific Cre-mediated gene deletion in VE-cadherin–CreERT2 mice as compared to Tie2-Cre mice.127

As far as valvular fibroblasts are concerned, the only published information available is from the Tcf21-CreERT2 knockin mouse line, which has targeted insertion of the Tam-inducible Cre recombinase, MerCreMer, at the Tcf21 locus.128 Following Tam treatment at E10.5, E18.5 hearts were analyzed for reporter activity using the R26RYFP reporter.129 Reporter expression was detectable in the atrioventricular valves and absent from the outflow tract valves. Although reporter expression seems to be present in the valvular fibroblasts at E18.5, Tam induction at different time points in cardiac development and at postnatal stages is needed to capture the spatiotemporal nature and the cell type
Because of the tremendous success of Wnt1-Cre mice in tracing NCC lineage, the Wnt1 promoter was also used to generate Wnt1-CreERT2 mice. Surprisingly, there has been no published literature so far about the use of Wnt1-CreERT2 mice in either cardiac NCC lineage mapping or NCC-specific Tam-dependent conditional deletion or overexpression of genes during heart development and in adults.

**Epicardium and Epicardium-Derived Cells**

Epicardium is the outermost mesothelial cellular layer of the heart, which plays essential roles in heart development and cardiac homeostasis, repair, and regeneration. In heart development, epicardium gives rise to cardiac fibroblasts by epicardial EMT. It also contributes to cardiac endothelium and coronary smooth muscle cells. Under pathological conditions such as after myocardial infarction, epicardial cells also undergo EMT and produce myofibroblasts, fibroblasts, and smooth muscles. Inducible epicardial cell-specific conditional gene targeting is becoming a powerful tool to dissect epicardial cell function during heart development and adult heart under both physiological and pathophysiological conditions. The Wt1-CreERT2 and Tcf21-CreERT2 are the only well-characterized inducible epicardial Cre mice currently available. Epicardial cell lineage cell tracking after Tam treatment showed that epicardial cells contribute to epicardium-derived cells and to cardiomycocytes. Lineage tracking also indicates that epicardium contributes to formation of the mammalian annulus fibrosis through EMT. Tam induction of Wt1-CreERT2 mice revealed that in uninjured postnatal hearts the epicardial cells were quiescent. Myocardial infarction stimulated formation of epicardium-derived cells, which remained in a thickened layer on the surface of the heart. The epicardium-derived cells did not adopt cardiomycocyte or coronary endothelial fates, but rather differentiated into mesenchymal cells expressing fibroblast and smooth muscle markers. Additional inducible epicardial Cre driver lines are needed to ensure and further validate these findings.

Tcf21-CreERT2 is another valuable Tam-inducible epicardial Cre driver line. Tam inductions were performed at 2 embryonic time points (E10.5 and E14.5) to determine the ROSA26 reporter expression in epicardium and its derivatives. By contrast, hearts from E18.5 embryos that were induced at E14.5 had very little labeling of epicardial cells and showed reporter expression predominantly in cells scattered within the myocardium (perhaps epicardium-derived cells). The authors suggested that this pattern of expression was likely caused by migration of cells from the epicardium into the myocardium following epicardial EMT. Cre activity was also analyzed in 4-week-old hearts where it was detected in a vast majority of interstitial cells that were not endothelial or vascular smooth muscle cells. Tcf21 is heavily expressed in proepicardium at E9.5 during heart development. It remains to be seen whether Tcf21-CreERT2 mice can drive Cre-activity in the proepicardium during early stages of heart development. This will be very informative for the cardiac research community.
Cardiac Conduction System

Cardiac conduction system (CCS) function is essential for proper rhythmic contraction of the heart. The CCS is made of a network of cardiomyocytes, which generate and propagate electric impulses in the heart (Figure 1). Electric impulses are produced in the sino-atrial node, which propagate through fast-conducting atrial myocardium and later delayed at the AV node. From the AV node, the electric impulse is rapidly conducted through the ventricular conduction system, consisting of the AV (His) bundle and bundle branches and peripheral Purkinje network. Electric impulses are finally transmitted from Purkinje fibers to working myocardium. Several genes that are important for the CCS are also required for myocardial development and function.

Although there are several good inducible Cre mouse models available for specifically targeting genes in myocardium, there are fewer choices for the CCS. HCN4-CreERT2 knockin (at HCN4 locus) mice drive Tam-dependent Cre activity in the sino-atrial node and AV node, but not the AV bundle or bundle branches. Tamoxifen-inducible Cre activity in Cx40-CreERT2 knockin (at Cx40 locus) mice was seen in the AV bundle, bundle branches, and Purkinje fibers, but not the AV node. A major pitfall of Cx40-CreERT2 mice is that the Cre activity is also present in non-CCS (ie, atrial cardiomyocytes, coronary vessels). Recently, mink-CreERT2 BAC transgenic mice were made. Tam-induced Cre activity was found in the AV node, AV bundle, and bundle branches of adult transgenic mice. There are concerns that it will be difficult to interpret the findings based on the haploinsufficient HCN4-CreERT2 and Cx40-CreERT2 knockin mice because both HCN4 and Cx40 are important players in the CCS. This issue can be circumvented in the mink-CreERT2 transgenic mice, which are CCS-specific and have an intact endogenous mink locus.

Perspectives

Site-specific recombinases have proven to be remarkable tools for many aspects of mouse experimentation. However, these tools have limitations. Knowledge of their strengths and weaknesses is vital for optimizing their application. There are several good Cre driver lines to induce gene manipulations in myocardium. There is a need for more Cre driver lines for inducible gene targeting in epicardium. There is no satisfactory Cre driver line for inducible conditional gene targeting in cardiac valve endocardium and valve mesenchyme for both mouse embryos and adult mice. Serious efforts are needed to identify, develop, and validate these resources for the cardiac valve community.

Because conditional KO or transgenic mouse technology limits gene mutation or overexpression to a specific cell type/tissue/organ or to a specific life stage, generation of improved mouse models of adult cardiac diseases heavily depends on the progress and innovation in inducible conditional gene targeting technology. The difference between conventional conditional and inducible conditional gene targeting approaches has recently been exemplified by Braf gene inactivation in forebrain neurons where both common and distinct phenotypes were found. This also applies to cardiovascular disease studies. For example, although considerable progress has been made in the past 20 years in delineating mechanisms underlying cardiovascular disease by using conventional gene targeting strategies, future progress will come largely from inducible conditional gene targeting approaches. These can better model the human disease conditions and identify pathways involved in unintended side-effects of potential therapies.

Sources of Funding

This study was supported by funding from Program for Developmental Biology and Neonatal Medicine at Indiana University College of Medicine (to M.A.), and the BIO5 Institute at University of Arizona (to T.D.).

Disclosures

None.

References


Cardiac-Specific Inducible Gene Targeting


73. Yalcin B, Wong K, Agam A, et al. Sequence-based characterization of


102. Agah R, Frenkel PA, French BA, Michael LH, Overbeek PA, Schneider MD. Gene recombination in postmitotic cells. Targeted expression of


Cardiac-Specific Inducible and Conditional Gene Targeting in Mice
Thomas Doetschman and Mohamad Azhar

doi: 10.1161/CIRCRESAHA.112.265066
Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2012 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/110/11/1498

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org/subscriptions/